Sarepta Therapeutics, Inc.
SRPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $11,560,169 | $8,909,939 | $11,345,895 | $7,317,643 |
| - Cash | $1,103,010 | $428,430 | $966,777 | $2,115,869 |
| + Debt | $1,343,070 | $1,396,808 | $1,617,359 | $1,138,388 |
| Enterprise Value | $11,800,229 | $9,878,317 | $11,996,477 | $6,340,162 |
| Revenue | $1,901,979 | $1,243,336 | $933,013 | $701,887 |
| % Growth | 53% | 33.3% | 32.9% | – |
| Gross Profit | $1,582,880 | $1,092,993 | $793,024 | $604,838 |
| % Margin | 83.2% | 87.9% | 85% | 86.2% |
| EBITDA | $333,056 | -$439,196 | -$582,116 | -$317,406 |
| % Margin | 17.5% | -35.3% | -62.4% | -45.2% |
| Net Income | $235,239 | -$535,977 | -$703,488 | -$418,780 |
| % Margin | 12.4% | -43.1% | -75.4% | -59.7% |
| EPS Diluted | 2.34 | -5.8 | -8.03 | -5.15 |
| % Growth | 140.3% | 27.8% | -55.9% | – |
| Operating Cash Flow | -$205,787 | -$500,993 | -$325,346 | -$443,172 |
| Capital Expenditures | -$136,956 | -$87,345 | -$32,251 | -$38,490 |
| Free Cash Flow | -$342,743 | -$588,338 | -$357,597 | -$481,662 |